Association of Interferon Lambda 3 and 4 Gene SNPs and Their Expression with COVID-19 Disease Severity: A Cross-Sectional Study

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Peiris JSM, Chu C-M, Cheng V-C-C, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767–1772. doi:10.1016/S0140-6736(03)13412-5
   PubMed Web of Science ®Google Scholar
• Wong C, Lam C, Wu A, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103. doi:10.1111/j.1365-2249.2004.02415.x
   PubMed Web of Science ®Google Scholar
• Ye L, Schnepf D, Staeheli P. Interferon-λ orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol. 2019;19(10):614–625. doi:10.1038/s41577-019-0182-z
   PubMed Web of Science ®Google Scholar
• Kelly A, Fahey R, Fletcher JM, et al. CD141+ myeloid dendritic cells are enriched in healthy human liver. J Hepatol. 2014;60(1):135–142. doi:10.1016/j.jhep.2013.08.007
   PubMed Web of Science ®Google Scholar
• Boulant S, Forero A, Santer DM, Broggi A. Type III interferons: emerging roles beyond antiviral barrier defense. Front Immunol. 2022;13:1030812. doi:10.3389/fimmu.2022.1030812
   PubMed Web of Science ®Google Scholar
• Andreakos E, Tsiodras S. COVID‐19: lambda interferon against viral load and hyperinflammation. EMBO Mol Med. 2020;12(6):e12465. doi:10.15252/emmm.202012465
   PubMed Web of Science ®Google Scholar
• Zanoni I. Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19? Curr Opin Virol. 2021;50:119–127. doi:10.1016/j.coviro.2021.08.004
   PubMed Web of Science ®Google Scholar
• Rand U, Kupke SY, Shkarlet H, et al. Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity. Cells. 2021;10(7):1756. doi:10.3390/cells10071756
   PubMed Web of Science ®Google Scholar
• O’Brien TR, Thomas DL, Jackson SS, Prokunina-Olsson L, Donnelly RP, Hartmann R. Weak induction of interferon expression by SARS-CoV-2 supports clinical trials of interferon lambda to treat early COVID-19. Clin Infect Dis. 2020;71(6):1410–1412. doi:10.1093/cid/ciaa453
   PubMed Web of Science ®Google Scholar
• Hamming OJ, Terczyńska‐Dyla E, Vieyres G, et al. Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 2013;32(23):3055–3065. doi:10.1038/emboj.2013.232
   PubMed Web of Science ®Google Scholar
• Sorrentino L, Silvestri V, Oliveto G, et al. Distribution of interferon lambda 4 single nucleotide polymorphism rs11322783 genotypes in patients with COVID-19. Microorganisms. 2022;10(2):363. doi:10.3390/microorganisms10020363
   PubMed Web of Science ®Google Scholar
• Li W, Lewis‐Antes A, Huang J, Balan M, Kotenko S. Regulation of apoptosis by type III interferons. Cell Prolif. 2008;41(6):960–979. doi:10.1111/j.1365-2184.2008.00558.x
   PubMed Web of Science ®Google Scholar
• Bakadia BM, He F, Souho T, et al. Prevention and treatment of COVID-19: focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. Biomed Pharmacother. 2021;133:111008.
   PubMed Web of Science ®Google Scholar
• Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut. 2011;60(9):1284–1293. doi:10.1136/gut.2010.222976
   PubMed Web of Science ®Google Scholar
• Matsuura K, Tanaka Y. Host genetic variants influencing the clinical course of hepatitis C virus infection. J Med Virol. 2016;88(2):185–195. doi:10.1002/jmv.24334
   PubMed Web of Science ®Google Scholar
• Amodio E, Pipitone RM, Grimaudo S, et al. SARS-CoV-2 viral load, IFNλ polymorphisms and the course of COVID-19: an observational study. J Clin Med. 2020;9(10):3315. doi:10.3390/jcm9103315
   PubMed Web of Science ®Google Scholar
• Saponi-Cortes JMR, Rivas MD, Calle F, et al. IFNL4 genetic variant can predispose to COVID-19. Sci Rep. 2021;11(1):21185.
   PubMed Web of Science ®Google Scholar
• Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–171. doi:10.1038/ng.2521
   PubMed Web of Science ®Google Scholar
• COVID-19 dashboard [Internet]; 2022. Available from: https://covid19.who.int/. Accessed October 3, 2023.
   Google Scholar
• Ghulam U, Nazim F, Farooqui N, et al. Analysis of differential gene expression of pro-inflammatory cytokines in the nasopharyngeal milieu of mild & severe COVID-19 cases. PLoS One. 2022;17(12):e0279270. doi:10.1371/journal.pone.0279270
   PubMed Web of Science ®Google Scholar
• Son K-B, Lee T-J, Hwang S-S. Disease severity classification and COVID-19 outcomes, Republic of Korea. Bull World Health Organ. 2021;99(1):62. doi:10.2471/BLT.20.257758
   PubMed Web of Science ®Google Scholar
• Ahmed MA, Anwar MF, Ahmed K, et al. Baseline MMP expression in periapical granuloma and its relationship with periapical wound healing after surgical endodontic treatment. BMC Oral Health. 2021;21(1):1–9. doi:10.1186/s12903-021-01904-6
   PubMed Web of Science ®Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. methods. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
   PubMed Web of Science ®Google Scholar
• O’Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-λ4: the paradoxical new member of the interferon lambda family. J Interferon Cytokine Res. 2014;34(11):829–838. doi:10.1089/jir.2013.0136
   PubMed Web of Science ®Google Scholar
• World Health Organization. Therapeutics and COVID-19: living guideline, 20 November 2020. World Health Organization; 2020.
   Google Scholar
• Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8(12):1233–1244. doi:10.1016/S2213-2600(20)30404-5
   PubMed Web of Science ®Google Scholar
• Sposito B, Broggi A, Pandolfi L, et al. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell. 2021;184(19):4953–68. e16. doi:10.1016/j.cell.2021.08.016
   PubMed Web of Science ®Google Scholar
• Broggi A, Ghosh S, Sposito B, et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science. 2020;369(6504):706–712. doi:10.1126/science.abc3545
   PubMed Web of Science ®Google Scholar
• Major J, Crotta S, Llorian M, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science. 2020;369(6504):712–717. doi:10.1126/science.abc2061
   PubMed Web of Science ®Google Scholar
• Akamatsu MA, de Castro JT, Takano CY, Ho PL. Off balance: interferons in COVID-19 lung infections. EBioMedicine. 2021;73:103642. doi:10.1016/j.ebiom.2021.103642
   PubMed Web of Science ®Google Scholar
• Cardoso NP, Mansilla FC, Benedetti E, et al. Bovine interferon lambda is a potent antiviral against SARS-CoV-2 infection in vitro. Front Veter Sci. 2020;7:603622. doi:10.3389/fvets.2020.603622
   PubMed Web of Science ®Google Scholar
• Lowery SA, Sariol A, Perlman S. Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19. Cell Host Microbe. 2021;29(7):1052–1062. doi:10.1016/j.chom.2021.05.004
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Pierangeli A, Frasca F, et al. Differential induction of type I and III interferon genes in the upper respiratory tract of patients with coronavirus disease 2019 (COVID-19). Virus Res. 2021;295:198283. doi:10.1016/j.virusres.2020.198283
   PubMed Web of Science ®Google Scholar
• Agwa SH, Kamel MM, Elghazaly H, et al. Association between interferon-lambda-3 rs12979860, tll1 rs17047200 and ddr1 rs4618569 variant polymorphisms with the course and outcome of SARS-CoV-2 patients. Genes. 2021;12(6):830. doi:10.3390/genes12060830
   PubMed Web of Science ®Google Scholar
• Rahimi P, Tarharoudi R, Rahimpour A, et al. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients. Virol J. 2021;18(1):1–7. doi:10.1186/s12985-021-01692-z
   PubMed Web of Science ®Google Scholar
• Shahbazi M, Amri Maleh P, Bagherzadeh M, et al. Linkage of lambda interferons in protection against severe COVID-19. J Interferon Cytokine Res. 2021;41(4):149–152. doi:10.1089/jir.2020.0187
   PubMed Web of Science ®Google Scholar
• Sorrentino L, Fracella M, Frasca F, et al. Alterations in the expression of IFN lambda, IFN gamma and toll-like receptors in severe COVID-19 patients. Microorganisms. 2023;11(3):689. doi:10.3390/microorganisms11030689
   PubMed Web of Science ®Google Scholar
• Guimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385(5):406–415. doi:10.1056/NEJMoa2101643
   PubMed Web of Science ®Google Scholar
• Singh PK, Lalwani LK, Govindagoudar MB, et al. Tofacitinib associated with reduced intubation rates in the management of severe COVID-19 pneumonia: a preliminary experience. Indian J Crit Care Med. 2021;25(10):1108. doi:10.5005/jp-journals-10071-23964
   PubMed Web of Science ®Google Scholar
• Kim M-H, Salloum S, Wang JY, et al. Type I, II, and III interferon signatures correspond to coronavirus disease 2019 severity. J Infect Dis. 2021;224(5):777–782. doi:10.1093/infdis/jiab288
   PubMed Web of Science ®Google Scholar
• Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28–33. doi:10.1038/s41591-020-01202-8
   PubMed Web of Science ®Google Scholar
• Sarkar A, Sanyal S, Majumdar A, et al. Development of lab score system for predicting COVID-19 patient severity: a retrospective analysis. PLoS One. 2022;17(9):e0273006. doi:10.1371/journal.pone.0273006
   PubMed Web of Science ®Google Scholar
• Pujani M, Raychaudhuri S, Singh M, et al. An analysis of hematological, coagulation and biochemical markers in COVID-19 disease and their association with clinical severity and mortality: an Indian outlook. Am J Blood Res. 2021;11(6):580.
   PubMedGoogle Scholar